CT-2500

CT-2500 is an investigational small molecule drug candidate being developed by Circadian Therapeutics for the treatment of neurodegenerative disorders, specifically Parkinson's disease and Alzheimer's disease. Circadian Therapeutics, a spin-out from the University of Oxford, focuses on the molecular control of circadian rhythms, which are frequently disrupted in patients with neurodegeneration. CT-2500 is designed to target the underlying molecular mechanisms of the circadian clock to restore physiological rhythmicity. While the specific biological target has not been publicly disclosed, the therapeutic approach aims to address the circadian rhythm disruption (CRD) that contributes to the progression and symptomatic burden of these diseases.